Trial Profile

A pivotal clinical trial comparing the proprietary Valacyclovir Oral Suspension (200 mg/mL) with Valtrex® tablets

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Valaciclovir (Primary) ; Valaciclovir
Indications Herpes labialis; Herpes simplex virus infections; Herpes zoster; Herpesvirus infections
Focus Registrational; Therapeutic Use
Sponsors Hyloris Pharmaceuticals

Most Recent Events

29 Dec 2023 New trial record
26 Dec 2023 According to Hyloris Pharmaceuticals Media Release, results from this study allows for further preparation of a NDA for submission to the FDA expected in 2024.
26 Dec 2023 Results published in the Hyloris Pharmaceuticals Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com